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INTRODUCTION
It is now widely acknowledged that reviews by independent eth-
ics committees are essential for biomedical research involving hu-
man subjects. Tokushima University is located in Tokushima in
the rural Shikoku region of Japan. The first ethics committee in
Japan was established at Tokushima University in 1982 to review
investigator- initiated biomedical research. Notably, this committee
was not formed as a response to national directives. However, the
government later developed ethics guidelines, such as the Ethical
Guidelines for Clinical Studies that were established in 2003. This
changed the situation at the national level, and reviewing research
ethics became a key process in institutions that conduct biomedi-
cal research.
In this review, we describe the activity of the ethics committee
at Tokushima University during the last thirty years. In addition,
we discuss the infrastructure that best supports the activities of this
committee, such as set-up of the Academic Office of the Ethics
Committee, research ethics education seminars, and research eth-
ics consultations. Finally, this article addresses the issues that eth-
ics committees now face and discusses future directions.
THE FIRST ETHICS COMMITTEE IN JAPAN
The first ethics committee in Japan was proposed at Tokushima
University by a fertility researcher. As background, we note that
sterility is a serious problem, and in vitro fertilization (IVF) is a
medical procedure that was developed to overcome sterility. Al-
though IVF is currently a well -established clinical practice, it was
an innovative therapy back in the 1970s (1). The procedure was
developed in the United Kingdom by Steptoe and Edwards, and
in July 1978, Louise Brown became the world’s first “test - tube”
baby. In April of 1981, Prof. Takahide Mori arrived at Tokushima
University School of Medicine as a Professor in the Department of
Gynecology and Obstetrics. His focus was IVF research, and he
began to establish a laboratory and to train physicians. In Septem-
ber of 1982, the department prepared to offer in vitro fertilization
as a clinical procedure at Tokushima University. Although Prof.
Mori was quite confident that IVF was an appropriate procedure
from both a clinical and a patient viewpoint, he was aware that a
physician’s confidence alone is not sufficient for pioneering inno-
vative therapy-societal approval is needed as well. To ensure this,
he discussed the matter with Prof. Takao Saito, the Director of the
Hospital, and with Prof. Masuhide Miyao, the Dean of the School
of Medicine. They agreed that it would be appropriate to set up an
ethics committee to ensure that the research was acceptable from
a societal point of view.
On December 14, 1982, the Ethics Committee of Tokushima Uni-
versity School of Medicine held its first meeting. The Committee
consisted of 8 members. These were dean of the school of medi-
cine, director of the university hospital, 2 professors of basic medi-
cine, 2 professors of clinical medicine and 2 academic experts other
than medicine (2). Over the course of 11 meetings, 11 external spe-
cialists were invited to attend. Although the original goal of the
committee was to ensure the social acceptability of proposed re-
search, ethical issues such as respect for persons, beneficence,
and justice were also considered during the review process. On
April 12, 1983, the committee approved the proposed IVF project,
and in March of 1984, the third “test - tube” baby in Japan was born
at Tokushima University.
THE ETHICS COMMITTEE IN THE 1980s AND 1990s
IN JAPAN AND AT TOKUSHIMA UNIVERSITY
After the establishment of the Ethics Committee of Tokushima
University School of Medicine, the number of ethics committees
gradually increased in Japan. It is notable that ethics committees
were not mandatory in medical schools. Like Tokushima Univer-
sity, one motive for establishing separate ethics committees at each
medical school was to deal with some difficult problems that phy-
sicians had never faced before. Sakai suggested other motives as
well (3). One motive was to address issues related to conforming
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to the tenants of the Declaration of Helsinki. Second, developments
in the United States made Japan realize that the clinical applica-
tions of new medical technologies needed prior review by each re-
search institution.
To assess the state of ethics committees in Japan in the early
1990s, Saito (4) surveyed 80 medical schools by questionnaire in
1991 and reported that ethics committees had been established in
79 of the 80 schools. He considered it fortunate that committees
were established voluntarily by members of each campus rather
than in response to national directives or legislation.
In 1992, ten years after the establishment of the Ethics Commit-
tee of Tokushima University School of Medicine, another commit-
tee was established at the University Hospital as a sub-commit-
tee of the Ethics Committee of Tokushima University School of
Medicine. The sub-committee at Tokushima University Hospital
did not deal mainly with urgent issues, such as those posed by
IVF, but with more ordinary issues in medical practice and research.
Gradually, the number of protocols seeking ethics committee ap-
proval increased.
TWO MAJOR CHANGES IN THE REGULATION OF
CLINICAL STUDIES THAT OCCURRED AROUND 2000
IN JAPAN
From a regulatory viewpoint, there were two major changes
around 2000 in Japan in the field of biomedical research involving
human subjects. The first was a change in clinical trials for drug
approval, also called registration trials, which are regulated by
pharmaceutical laws. In 1998, Good Clinical Practice (GCP) guide-
lines, which were originally approved by the International Confer-
ence on Harmonisation of Technical Requirements for Registration
of Pharmaceuticals for Human Use (ICH), were deployed for all
registration trials. Prior to this, most university hospitals had dif-
ferent types of committees for reviewing registration trials, and
they had to revise these committees to conform to GCP guidelines.
At Tokushima University Hospital, the structure and management
of an already-established committee (which was separate from the
Ethics Committee of Tokushima University Hospital) was substan-
tially altered and strengthened.
The second change was the establishment of ethics guidelines
by the appropriate government ministries (5). These guidelines
apply to clinical studies other than registration trials. The Japanese
government enforced the Ethical Guidelines for Human Genome
and Gene Analysis Research as guidelines for research in 2001 ;
the Ethical Guidelines for Epidemiological Research were enforced
in 2002, and the Ethical Guidelines for Clinical Studies were en-
forced in 2003. The applicable research fields were designated by
these guidelines, and ethics committees that had been established
voluntarily became mandatory for medical institutions that conduct
these types of research. Accordingly, from a practical standpoint,
matters related to the maintenance of ethical committees had to be
addressed by each institution. Notably, even at present, GCP is
not applied to clinical studies other than those related to the ap-
proval of drugs and medical devices, except for regenerative medi-
cine. As for regenerative medicine, a new safety law was passed in
2013 and will be enforced in 2014. In addition to ensuring the safety
of regenerative medicine, this new law and other related Japanese
policies focus on providing a fast - track approval process for stem
cell therapies (6).
THE ETHICS COMMITTEE AND ESTABLISHMENT
OF THE ACADEMIC OFFICE OF THE ETHICS COM-
MITTEE AROUND 2000 AT TOKUSHIMA UNIVER-
SITY HOSPITAL
In response to enforcement of these guidelines in 2001-2003,
the number of protocols increased (Figure 1). Although the Ethics
Committee had an administrative division (section of the adminis-
trative office of Tokushima University Hospital), additional infra-
structure was needed to support it. The increased workload was
observed in Japanese ethics committees at other institutions as
well (7).
In addition, to provide infrastructure for registration trials and to
comply with the GCP guidelines, the Clinical Trial Center for De-
velopmental Therapeutics (CTCDT) was established in April of
1999 at Tokushima University Hospital. Originally, the CTCDT
aimed to manage and promote registration trials by liaising with
clinical research coordinators (8) and by educating investigators
about registration trials. The CTCDT was set up to meet the re-
quirements of the various ethics guidelines, and in July of 2002,
the Academic Office of the Ethics Committee was set-up as part
of the CTCDT. Subsequently, in October of 2003, the sub-commit-
tee was renamed the “Ethics Committee of Tokushima University
Figure 1
The annual number of protocols submitted to the Ethics Committee of Tokushima University Hospital.
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Hospital” and became the main committee for reviewing biomedi-
cal research involving human subjects, including investigator- in-
itiated clinical trials.
THE CURRENT STATUS OF THE ETHICS COMMIT-
TEE AND THE ACADEMIC OFFICE OF TOKUSHIMA
UNIVERSITY HOSPITAL
The Ethics Committee of Tokushima University Hospital con-
sists of 13 members. Of these, 5 are from outside the institution
and 2 are women, and the member system is set in accordance
with governmental ethical guidelines. Meetings are held monthly
and have the Office for Human Research Protections (OHRP) reg-
istration number. As shown in Figure 1, the number of protocols
submitted annually to the ethics committee at Tokushima Univer-
sity Hospital continues to increase.
The Academic Office of the Ethics Committee works with spe-
cific section of the administrative office of Tokushima University
Hospital. One medical doctor, two scientists, and one officer, none
of whom are committee members, have roles at the Academic Of-
fice of the Ethics Committee. The aims of the Academic Office of
the Ethics Committee include administrating the proceedings of the
ethics committee, providing ethics education to investigators in col-
laboration with the ethics committee under the supervision of the
director of the hospital, advising investigators, and conducting pre-
checks of documents. Pre-checking documents by the Academic
Office takes about 5-6 hours per protocol. The main objective is not
to review the protocols per se, but to suggest ways for the inves-
tigators to facilitate the review process and make the review proc-
ess more efficient. For example, the status of clinical trial regis-
tration for interventional studies (9) is checked by the Academic
Office before ethics review by the committee. In practice, the Aca-
demic Office sometimes suggests additional information that may
be needed or suggests revision of the documents.
To ensure compliance and the ethical conduct of clinical stud-
ies, each Japanese institution established a department that works
closely with their ethics committee. Some issues face these depart-
ments, such as how to deal with new issues, staff shortages, the
career path of the staff, and how best to ensure that the staff re-
mains up-to-date.
RESEARCH ETHICS EDUCATION AND CONSULTA-
TION AT TOKUSHIMA UNIVERSITY HOSPITAL
Similar to institutional review boards in the United States, ethics
committees in Japan are involved with reviewing research protocols.
In addition, they are also in charge of developing policy, education,
and consultation, which is similar to hospital ethics committees in
the United States (7). In 1995, a survey of ethics committees at
Japanese medical schools showed that 17.5% offered consultations,
and 21.3% provided educational resources to investigators (7). We
use two major approaches in ethics education for investigators at
the University Hospital. First, we have our investigators registra-
tion rule and offer educational seminars regularly. Second, the
Academic Office advises investigators via research ethics consul-
tations.
The registration rule for physicians was originally established in
2001 in response to the GCP, and it was aimed at maintaining the
quality of registration trials at Tokushima University Hospital. In
the rule, attendance at a clinical trial seminar became mandatory
to be selected as an investigator for registration trials.
In 2009, the revised Ethical Guidelines for Clinical Studies came
into effect, and coverage of our registration rule was expanded in
order to maintain the quality of investigator- initiated studies at
Tokushima University Hospital. According to the new rule, atten-
dance at a clinical trial seminar became mandatory for all investi-
gators requesting research review by the Ethics Committee of
Tokushima University Hospital.
Clinical trial seminars began in 2000 for investigators at Tokushima
University. Practically, we accept participation of investigators out-
side Tokushima University and we started to enlighten that semi-
nars are open to all investigators outside Tokushima University in
2006. Regular seminars are held monthly by the staff of the CTCDT,
and face-to- face contact at the occasion is encouraged for future
partnerships between investigators and the staff of the CTCDT.
The seminars address the scientific and ethical aspects of clinical
studies and offer practical tips for requesting research review by
the Ethics Committee of Tokushima University Hospital and for
conducting clinical studies at Tokushima University. In addition,
seminars by specialists are held 4-6 times per year. Figure 2 shows
the annual number of participants in the clinical trial seminars ; it
is clear that the number increased rapidly after expansion of the
rule. Most participants are investigators at postgraduate level. Al-
though undergraduate investigators are encouraged to attend these
seminars, closer cooperation with undergraduate ethics education
remains as an important issue. Similar educational systems are op-
erated, for example, at the institute and medical organization levels,
and recent attention has been focused on the establishment of na-
tionwide system or authorization in Japan.
The Academic Office of the Ethics Committee provided advice
to a total of 950 inquiries from investigators in 2014. Most of these
were investigators in clinical departments, but some came from
other departments, and a few came from outside of Tokushima Uni-
versity. The consultations were mainly regarding administrative
matters, with consultations regarding research itself accounted for
about 10%. To respond more effectively to investigator inquiries,
we set up regular time for research ethics consultations in 2012.
Although research ethics consultations are now common in the
United States (10, 11), only a small number of institutions in Ja-
pan offer this service (12). We provided 30 research ethics con-
sultations in 2014. Accordingly, promoting and maintaining high
quality research ethics consultations remains an important issue
at Tokushima University Hospital as well as at other Japanese re-
search institutions.
In 2012, we celebrated 30 years of ethics committee in Tokushima
University by holding a special symposium focusing on research
ethics education in the new era. After Prof. Reidar K. Lie of the
University of Bergen gave a special lecture about the global status
of research ethics, other invited Japanese leaders in research eth-
ics education (Drs. Yutaka Matsuoka, Fumitaka Nagamura, Kenji
Matsui and Shimon Tashiro) discussed the challenges in research
ethics that face investigators. We consider communication among
those who play important roles in research ethics education and
consultation to be very important for the acceptance and use of re-
search ethics committees.
BIOMEDICAL RESEARCH IN JAPAN AND FUTURE
DIRECTIONS FOR ETHICS COMMITTEES
Japanese biomedical research now faces the repercussions from
a major scandal. Briefly, data related to a blockbuster hypertension
drug was manipulated in a multi - institutional clinical trial, and ex-
posure of this manipulation resulted in the retraction of published
papers (13). Currently, even for clinical trials conducted from the
interest of industry, GCP does not apply outside drug approval
scheme (14), and Japan has no national system to ensure research
integrity. Research misconduct may lead to violent protests to pro-
tect research participants ; thus, each ethics committee must take
active steps to remedy the current situation.
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We must also work to ensure that the ethics committees provide
sound, high quality guidance to researchers. Although the struc-
ture and function of ethics committees are basically defined by gov-
ernmental ethics guidelines, the system that ensures the quality of
ethics committees is still unsatisfactory in Japan. For example, no
one even knows the exact number of ethics committees in Japan.
In 2012, the Ministry of Health, Labor and Welfare initiated a reg-
istration system for ethics committees, and voluntary registration
is encouraged. According to the registration system website (15),
a total of 1422 ethics committees were registered as of May 1, 2015,
which seems like quite a lot of ethics committees, and governmen-
tal certification of ethics committees has now begun in 2015. Until
now, each institute and hospital has established their own ethics
committee, but we are now discussing whether it would be useful
to have a single ethics committee for use by several institutions in
order to offer high quality advice and education.
As for the situation in the Tokushima prefecture, Tokushima
University Hospital established the Tokushima Network for Clini-
cal Trials in collaboration with the Tokushima Medical Association
in 2004 (16) in response to a plan for promoting registration trials
by the Ministry of Health, Labor and Welfare and the Ministry of
Education, Culture, Sports, Science and Technology of Japan. The
investigator registration rule now applies to registration trials at
medical institutions that are in the same network as Tokushima
University Hospital, but it does not cover all clinical studies.
In several countries in Europe, region-based ethics committees,
which are called local research ethics committee, play roles in the
ethical conduct of research (17). Although it is possible for local
investigators to seek an ethics review from committees that are part
of medical organizations (18), especially medical clinics, it seems
appropriate that the ethics committee of a university hospital also
act as a local research ethics committee i.e. provide education and
consultation services to other, perhaps smaller, local institutions.
In a survey of the performance of clinical studies and ethics com-
mittees in Tokushima prefecture, 170 medical institutions cite the
following primary reasons for a lack of experience in conducting
clinical research : no arrangement with an ethics committee, no
interest in clinical research, a lack of available assistants, and no
opportunity to participate in clinical research (19). Because of
the voluntary nature of ethics committees when they were first
established, Japanese ethics committees often lack robust financial
support. These practical issues, i.e. access to ethics committees
and financial support, must be addressed, and communication be-
tween hospitals and clinics that are part of the “Tokushima Net-
work for Clinical Trials” will serve as the foundation for this to
happen.
Recent attention has been focused on the functions of ethics com-
mittees at post-approval phase. In the first place, the post-approval
state of each study was not monitored in most institutions. We
started annual status survey of approved studies in 2003 prior to
the indication by the revised Ethical Guidelines for Clinical Studies
in 2009. Nevertheless, the contribution of ethics committee to post-
approval issues is not still satisfactory. System that enables ethics
committees to contribute effectively to post-approval issues, such
as adequate publication securing research integrity, ancillary care
and proper returning of study results to participants, should be
established.
CONCLUSIONS
Thirty years ago, investigators at Tokushima University who
were trying to popularize IVF, then a new medical procedure, es-
tablished a system for the ethical conduct of biomedical research.
In preparing of this manuscript, two governmental guidelines, the
Ethical Guidelines for Epidemiological Research and the Ethical
Guidelines for Clinical Studies, have been integrated and new guide-
lines, the Ethical Guidelines for Medical and Health Research In-
volving Human Subjects (20), were enforced in 2015. After consid-
ering the history and experience of this committee, we continue
to try to optimize the system to ensure oversight of the ethics of
biomedical research in Tokushima Prefecture based on the new
guidelines. This system may be appropriate for adaptation and use
throughout Japan and even worldwide.
Figure 2
The annual number of participants in clinical trial seminars hosted by the Clinical Trial Center for Developmental Therapeutics, Tokushima Uni-
versity Hospital.
The shaded regions of the columns represent participants from Tokushima University, while the white regions represent participant from other
institutions.
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